Table 1: Characteristics of the 4 included studies.
Reference | Year | Country | Study design | Specimen | Method | H. pylori (+) in epilepsy group (%) | H. pylori (+) in control group (%) | H. pylori (+) in epilepsy classification | P value |
Asadi-Pooya | 2012 | Iran | Case-control | Breath | 13C-UBT | 35/62 (56.45%) | 14/33 (42.42%) | IGE: 21/34; TLE: 14/28 The difference was not significant (P = 0.3) |
0.3 |
Okuda | 2004 | Japan | Case-control | Serum | ELISA | 19/75 (25.33%) | 5/71 (7.04%) | IGE: 9/22; ILE: 10/53 The difference was not significant |
< 0.05 |
Ozturk | 2007 | Turkey | Case-control | Serum | ELISA | 37/47 (78.72%) | 13/35 (37.14%) | Poor prognosis: 18/24 Good prognosis: 19/23 The difference was not significant (P > 0.05) |
< 0.001 |
Razak | 2012 | Malaysia | Case-control | Breath | 13C-UBT | 18/48 (37.50% | 17/47 -36.17%) | Generalised epilepsy: 5/19 Partial epilepsy: 13/29 The difference was not significant |
0.893 |
H.pylori- Helicobacter pylori; IGE- idiopathic generalized epilepsy; TLE- temporal lobe epilepsy; ILE- idiopathic localization-related epilepsy; ELISA- enzyme-linked immunosorbent assay; 13C-UBT- 13C urea breath test.